Jiangsu Hengrui Medicine
600276.SS
#545
Rank
A$65.64 B
Marketcap
A$9.89
Share price
-1.71%
Change (1 day)
-31.85%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Earnings for Jiangsu Hengrui Medicine (600276.SS)

Earnings in 2026 (TTM): A$2.16 Billion

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current earnings are A$4.65 Billion. In 2024 the company made an earning of A$1.42 Billion, an increase over its 2023 earnings that were of A$0.94 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Jiangsu Hengrui Medicine from 2002 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) A$2.16 B
2024 A$1.42 B50.59%
2023 A$0.94 B11.35%
2022 A$0.85 B-13.91%
2021 A$0.98 B-34.08%
2020 A$1.49 B16.28%
2019 A$1.28 B32.92%
2018 A$0.96 B20.82%
2017 A$0.80 B23.8%
2016 A$0.64 B11.25%
2015 A$0.58 B39.52%
2014 A$0.41 B20.71%
2013 A$0.34 B11.46%
2012 A$0.31 B29.6%
2011 A$0.23 B31.28%
2010 A$0.18 B27.89%
2009 A$0.14 B5.84%
2008 A$0.13 B79.89%
2007 A$74.95 M32.93%
2006 A$56.39 M38.14%
2005 A$40.82 M21.56%
2004 A$33.58 M13.95%
2003 A$29.47 M38.06%
2002 A$21.34 M